Results of a Cohort Model Analysis of the Cost-Effectiveness of Routine Immunization With 13-Valent Pneumococcal Conjugate Vaccine of Those Aged >= 65 Years in the Netherlands

摘要: Abstract Background: Community-acquired pneumonia and invasive pneumococcal disease are common among older people (ie, those aged ≥65 years). A new 13-valent conjugate vaccine (PCV-13) is under study in the Netherlands. Objective: The aim of this work was to model cost-effectiveness PCV-13 vaccination years Netherlands, both total population at increased risk for pneumonia, various levels efficacy (30%–90%) assumed. Methods: Our previously published updated include age-specific epidemio-logic data health-care utilization costs a hypothetical cohort adults This followed twice—once as unvaccinated once vaccinated—over time period 5 years, with differences between analyses reported. Outcome measures included costs, life-years gained (LYGs), quality-adjusted life-years, incremental ratios (ICERs). All were performed from societal perspective. Results: In model, ICER remained below €80,000/LYG, except when assumed protect only against bacteremic relatively low effectiveness (40%) combination high price (€65), indirect effects serotype replacement would largely offset direct effect vaccination. For assumptions, introduction widespread (assuming 60% noninvasive because serotypes, cost €50 per vaccinated person) associated ICERs varying cost-saving €50,676/LYG. Conclusions: analysis might be considered cost-effective, high-risk perspective, over 5-year horizon. main limitation uncertainty regarding how great proportion could attributed disease.